Orthofix Medical (NASDAQ:OFIX) Upgraded at StockNews.com

Orthofix Medical (NASDAQ:OFIX - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Friday.

OFIX has been the topic of several other reports. Roth Mkm reaffirmed a "buy" rating and set a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Canaccord Genuity Group started coverage on shares of Orthofix Medical in a research report on Wednesday, January 22nd. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Stifel Nicolaus raised shares of Orthofix Medical from a "hold" rating to a "buy" rating and increased their price objective for the company from $18.00 to $24.00 in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Orthofix Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.

Orthofix Medical Stock Down 0.7 %

Shares of OFIX stock traded down $0.13 during trading on Friday, reaching $18.20. The company's stock had a trading volume of 196,260 shares, compared to its average volume of 191,227. The business has a fifty day moving average price of $18.07 and a 200-day moving average price of $17.09. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. The company has a market cap of $695.42 million, a price-to-earnings ratio of -5.81 and a beta of 1.10. Orthofix Medical has a one year low of $12.08 and a one year high of $20.73.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.57). Orthofix Medical had a negative return on equity of 21.25% and a negative net margin of 15.18%. The business had revenue of $196.61 million during the quarter, compared to the consensus estimate of $196.60 million. During the same period in the prior year, the firm earned ($0.77) EPS. Analysts anticipate that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore sold 10,078 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the sale, the chief executive officer now directly owns 133,354 shares in the company, valued at $2,244,347.82. This represents a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the sale, the chief financial officer now owns 28,312 shares in the company, valued at $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,675 shares of company stock worth $423,238. Corporate insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Orthofix Medical

Large investors have recently bought and sold shares of the company. R Squared Ltd bought a new position in shares of Orthofix Medical in the fourth quarter worth about $50,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Orthofix Medical by 5.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company's stock worth $156,000 after acquiring an additional 559 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Orthofix Medical in the third quarter worth about $216,000. Quest Partners LLC lifted its holdings in shares of Orthofix Medical by 187.1% in the third quarter. Quest Partners LLC now owns 13,908 shares of the medical device company's stock worth $217,000 after acquiring an additional 9,063 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Orthofix Medical by 74.0% in the 3rd quarter. SG Americas Securities LLC now owns 17,117 shares of the medical device company's stock valued at $267,000 after buying an additional 7,278 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.